Pharmacovigilance [Pharmacovigilance update]

Détails

ID Serval
serval:BIB_FB76F57165B0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Pharmacovigilance [Pharmacovigilance update]
Périodique
Revue medicale suisse
Auteur(s)
Livio F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
10/01/2018
Peer-reviewed
Oui
Volume
14
Numéro
588-589
Pages
81-84
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients. Posaconazole: risk of overexposure when switching from oral suspension to tablets. Voriconazole: cutaneous squamous cell carcinoma under long-term therapy. Proton pump inhibitors : early exposure might increase fracture risk in young children.
Mots-clé
Carcinoma, Squamous Cell/drug therapy, Child, Denosumab/adverse effects, Humans, Pharmacovigilance, Skin Neoplasms/drug therapy, Spinal Fractures/chemically induced
Pubmed
Création de la notice
25/01/2018 20:32
Dernière modification de la notice
20/08/2019 16:26
Données d'usage